Full-Time

Manager II

Medical Legal Regulatory Review

Confirmed live in the last 24 hours

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Develops treatments for eye care diseases

Biotechnology
Healthcare

Compensation Overview

$107.2k - $150.2kAnnually

+ Bonus + Stock Equity

Senior, Expert

Irvine, CA, USA

Hybrid work model available; some travel may be required.

Category
Risk & Compliance
Legal & Compliance
Medical, Clinical & Veterinary

You match the following Tarsus Pharamceuticals's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s Degree in science or health-related discipline required.
  • 8+ years of relevant experience, with a minimum of 5 years as a regulatory affairs reviewer on MLR/PRC committee.
  • Broad knowledge of the pharmaceutical industry is preferred.
  • Detail-oriented with the ability to promptly assess documents for accuracy.
  • Strong interpersonal skills with the ability to influence others in a positive and effective manner.
  • Ability to work in a team.
  • Demonstrated ability to contribute to a continuous learning and process improvement.
  • Under the guidance of the Sr. Director, knowledgeable resource for regulatory advice on promotional, corporate, and other non-promotional initiatives in other departments.
  • Experience in interpreting regulations, guidelines, and policy statements, including comprehensive knowledge of applicable regulations with demonstrated expertise relevant to labeling.
Responsibilities
  • Review/approve promotional, corporate, and other non-promotional materials to assess for compliance with the applicable regulations, guidance documents, and internal policies/best practices.
  • Manage and help develop a regulatory labeling, advertising, and promotion function, including processes and systems.
  • Represent regulatory on the Medical, Legal, and Regulatory review committee. Represent the promotional regulatory perspective with cross-functional partners from Commercial, Medical Affairs, and Business Conduct (US Legal).
  • Serve as the Regulatory point of contact for the regulatory promotional perspective and rationale at regulatory project team meetings, labeling meetings, brand team meetings, as needed.
  • Review and interpret enforcement letters, keep current with industry changes relating to advertising and promotion, and interpret new guidance.
  • Track all 2253 submissions and health authority activity to aid in resource planning for R&D.
  • Manage and draft responses to Health Authorities' queries. Provide support at labeling-related negotiation meetings or teleconferences.
Desired Qualifications
  • Experience working with Veeva PromoMats Vault is a plus.
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution for treating Demodex Blepharitis, a condition affecting the eyelids. The company also has a pipeline of potential treatments for Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong commitment to ethical practices and compliance. Their goal is to provide effective treatments for patients suffering from these conditions while expanding their product offerings through research and strategic partnerships.

Company Size

201-500

Company Stage

IPO

Total Funding

$58.4M

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing awareness of Demodex blepharitis expands market for Tarsus's XDEMVY.
  • Telemedicine rise offers new marketing opportunities for Tarsus's products.
  • FDA's focus on unmet needs may expedite Tarsus's pipeline approvals.

What critics are saying

  • Increased competition in ophthalmic treatments challenges Tarsus's market position.
  • Potential clinical trial delays could affect Tarsus's product pipeline.
  • Supply chain constraints may hinder XDEMVY's production and distribution.

What makes Tarsus Pharamceuticals unique

  • Tarsus focuses on high unmet needs in ophthalmic and infectious diseases.
  • Their lead product, XDEMVY, is FDA-approved for Demodex blepharitis treatment.
  • Tarsus's pipeline includes innovative treatments for Lyme disease and Rosacea.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

0%

2 year growth

1%
MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).

The Manila Times
Nov 13th, 2024
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Tarsus welcomes Kate Goodrich, M.D., MHS, to its Board of Directors.

Vision Monday
Nov 12th, 2024
Tarsus Pharmaceuticals Appoints Elizabeth Yeu, MD, as Chief Medical Officer

IRVINE, Calif.- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company that applies proven science and new technology to eyecare to improve treatment for patients, has announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024.

Fierce Pharma
Aug 14th, 2024
Tarsus 'firing on all cylinders' as Xdemvy launch, sales force expansion roll ahead: CEO

Meanwhile, Tarsus in April picked up $200 million in financing from Pharmakon Advisors, on top of the $180 million equity offering the company pulled off earlier in the year.

Yahoo Finance
Apr 23rd, 2024
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP.